Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program

• Published in: Journal of the American College of Cardiology 2008-11, Vol.52 (20), p.1640-1648
• Main Authors: Blair, John E A, Zannad, Faiez, Konstam, Marvin A, Cook, Thomas, Traver, Brian, Burnett, Jr, John C, Grinfeld, Liliana, Krasa, Holly, Maggioni, Aldo P, Orlandi, Cesare, Swedberg, Karl, Udelson, James E, Zimmer, Christopher, Gheorghiade, Mihai
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Benzazepines - therapeutic use; Cardiology; Confidence intervals; Double-Blind Method; Drug therapy; Estimates; Female; Heart attacks; Heart failure; Heart Failure - drug therapy; Heart Failure - ethnology; Heart Failure - mortality; Heart Failure - surgery; Hospitalization; Humans; Internationality; Kaplan-Meier Estimate; Male; Middle Aged; Mortality; Myocardial Revascularization; Pacemaker, Artificial - utilization; Prospective Studies; Public health; Software; Vasopressins - antagonists & inhibitors
• ISSN: 0735-1097; 1558-3597
• DOI: 10.1016/j.jacc.2008.07.056

Our aim was to examine continental and regional differences in baseline characteristics and post-discharge clinical outcomes in the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. Continental and regional differences in clinical trials of acute heart failure syndromes (AHFS) have not been well studied. We analyzed data from the EVEREST trial, which randomized 4,133 patients hospitalized for worsening (HF) and left ventricular ejection fraction < or =40% to oral tolvaptan, a vasopressin antagonist, or placebo and followed for a median of 9.9 months. Baseline characteristics, mortality, and outcomes were analyzed across North America (n = 1,251), South America (n = 688), Western Europe (564 patients), and Eastern Europe (n = 1,619). There were major differences between the 4 groups in the severity, etiology, and management of HF. Unadjusted 1-year mortality and cardiovascular mortality/HF hospitalization were 30.4% and 52.5% in North America, 27.2% and 41.6% in South America, 27.1% and 47.3% in Western Europe, and 20.5% and 35.3% in Eastern Europe. After adjustment, South American patients had the highest overall mortality (hazard ratio: 1.42, 95% confidence interval: 1.15 to 1.76), while Eastern European patients had the lowest cardiovascular death and HF hospitalization rate (hazard ratio: 0.84, 95% confidence interval: 0.73 to 0.97), compared with patients in North America. Major continental and regional differences in HF severity, etiology, and management exist among AHFS patients, resulting in varied post-discharge outcomes, despite pre-defined selection criteria. These differences should be taken into account when planning global trials in AHFS. (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan [EVEREST]; NCT00071331).